Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-08-29 23:58:41 UTC |
---|
Update Date | 2021-09-26 22:48:56 UTC |
---|
HMDB ID | HMDB0242340 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol |
---|
Description | (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. Based on a literature review very few articles have been published on (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol. This compound has been identified in human blood as reported by (PMID: 31557052 ). (1r,7s)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | OC1=C2C3CCC(C3)C2=C(O)N1CCCCN1CCN(CC1)C1=NC=CC=N1 InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-16,27-28H,1-2,4-5,8-14H2 |
---|
Synonyms | Not Available |
---|
Chemical Formula | C21H29N5O2 |
---|
Average Molecular Weight | 383.496 |
---|
Monoisotopic Molecular Weight | 383.232125194 |
---|
IUPAC Name | 4-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-4-azatricyclo[5.2.1.0^{2,6}]deca-2,5-diene-3,5-diol |
---|
Traditional Name | 4-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-4-azatricyclo[5.2.1.0^{2,6}]deca-2,5-diene-3,5-diol |
---|
CAS Registry Number | Not Available |
---|
SMILES | OC1=C2C3CCC(C3)C2=C(O)N1CCCCN1CCN(CC1)C1=NC=CC=N1 |
---|
InChI Identifier | InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-16,27-28H,1-2,4-5,8-14H2 |
---|
InChI Key | XCISMQWGDMQWLH-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazinanes |
---|
Sub Class | Piperazines |
---|
Direct Parent | N-arylpiperazines |
---|
Alternative Parents | |
---|
Substituents | - N-arylpiperazine
- Isoindole or derivatives
- Dialkylarylamine
- N-alkylpiperazine
- Aminopyrimidine
- Substituted pyrrole
- Pyrimidine
- Heteroaromatic compound
- Pyrrole
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M+H]+ | 189.083 | 30932474 | DeepCCS | [M-H]- | 186.725 | 30932474 | DeepCCS | [M-2H]- | 220.326 | 30932474 | DeepCCS | [M+Na]+ | 195.678 | 30932474 |
Predicted Kovats Retention IndicesUnderivatizedMetabolite | SMILES | Kovats RI Value | Column Type | Reference |
---|
(1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol | OC1=C2C3CCC(C3)C2=C(O)N1CCCCN1CCN(CC1)C1=NC=CC=N1 | 3376.4 | Standard polar | 33892256 | (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol | OC1=C2C3CCC(C3)C2=C(O)N1CCCCN1CCN(CC1)C1=NC=CC=N1 | 3324.3 | Standard non polar | 33892256 | (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol | OC1=C2C3CCC(C3)C2=C(O)N1CCCCN1CCN(CC1)C1=NC=CC=N1 | 3501.5 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0m29-3941000000-d13829667e98f0590ea3 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 10V, Positive-QTOF | splash10-001i-0009000000-55c01f5447cf202b44f6 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 20V, Positive-QTOF | splash10-0159-0039000000-d9bdcc8bf4abd3305971 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 40V, Positive-QTOF | splash10-00di-2911000000-0d9fe1a3ff7a9dfd50a9 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 10V, Negative-QTOF | splash10-001i-0009000000-e7deffdfaa26ce263053 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 20V, Negative-QTOF | splash10-001i-0009000000-77e1d074b87ce2874f63 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (1R,7S)-4-[4-(4-Pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]deca-2,5-diene-3,5-diol 40V, Negative-QTOF | splash10-0c09-3933000000-5c4bc88219e09ff57514 | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|